[(1S,7R,8R)-7-[(Z)-2-甲基丁-2-烯酰基]氧基-2,3,5,6,7,8-六氢-1H-吡咯里嗪-1-基]甲基 (Z)-2-(羟基甲基)丁-2-烯酸酯 | 2492-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯里西啶类
• 中文名称: [(1S,7R,8R)-7-[(Z)-2-甲基丁-2-烯酰基]氧基-2,3,5,6,7,8-六氢-1H-吡咯里嗪-1-基]甲基 (Z)-2-(羟基甲基)丁-2-烯酸酯
• 中文别名: [(1S,7R,8R)-7-[(Z)-2-甲基丁-2-烯酰基]氧基-2,3,5,6,7,8-六氢-1H-吡咯里嗪-1-基]甲基(Z)-2-(羟基甲基)丁-2-烯酸酯
• 英文名称: sarracine
• 英文别名: (12Z)-18-hydroxy-(1αH)-12,13-didehydro-1,2-dihydro-13,14-seco-senecionan-11,16-dione；(12Z)-18-Hydroxy-(1αH)-12,13-didehydro-1,2-dihydro-13,14-seco-senecionan-11,16-dion；[(1S,7R,8R)-7-[(Z)-2-methylbut-2-enoyl]oxy-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl (Z)-2-(hydroxymethyl)but-2-enoate
• CAS: 2492-09-3
• 化学式: C₁₈H₂₇NO₅
• 分子量: 337.416
• InChiKey: YMUQRQKYYOWGPN-SLEGRLQASA-N

物化性质

• 熔点：
  51-2°C
• 沸点：
  457.8±35.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)
• LogP：
  2.769 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3502130A1

  公开（公告）日：2019-06-26

  Disclosed is a ligand regulated protein-protein interaction system based on a lipocalin-fold molecule comprising: (a) a lipocalin-fold molecule (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below, and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand, and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 µM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

  所公开的是一种基于脂钙蛋白折叠分子的配体调节蛋白质-蛋白质相互作用系统，该系统包括 (a) 脂钙蛋白折叠分子 (b) 低分子量为 1500 Da 或以下的脂钙蛋白-折叠配体，以及 (c) 脂钙蛋白-折叠结合相互作用伙伴、 其中脂钙素折叠分子可与脂钙素折叠配体结合；以及 其中与脂钙蛋白配体结合的脂钙蛋白-折叠分子与脂钙蛋白-折叠结合相互作用伙伴结合的亲和力比未与脂钙蛋白-折叠配体结合的脂钙蛋白-折叠分子的亲和力至少高 10 倍、 其中脂钙蛋白-折叠结合相互作用伙伴不是天然存在的蛋白质，它在任何脂钙蛋白-折叠配体存在下对任何天然存在的脂钙蛋白-折叠分子的亲和力小于10 µM。
• A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3860643A1

  公开（公告）日：2021-08-11
• [EN] A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)<br/>[FR] GROUPE DE RÉCEPTEURS D'ANTIGÈNES CHIMÉRIQUES (CAR)
  申请人：ST ANNA KINDERKREBSFORSCHUNG

  公开号：WO2020070289A1

  公开（公告）日：2020-04-09

  Disclosed is a group of chimeric antigen receptors (CARs) consisting of two, three or four CAR molecules, wherein each member of the group of CARs is different in its amino acid sequence from one another, and wherein each of the CAR molecules of the group comprise at least a transmembrane domain and an ectodomain, wherein the ectodomain comprises one or two antigen binding moieties and/or one or two binding sites to which other polypeptides each comprising at least an antigen binding moiety are able to bind; wherein the ectodomain of each CAR molecule of the group in its prevalent conformation is free of cysteine amino acid moieties which are able to form intermolecular disulphide bonds with other CAR molecules of the group, respectively, and wherein each CAR molecule of the group comprises at least one heterodimerization domain.
• [EN] A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)<br/>[FR] GROUPE DE RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES (CAR)
  申请人：ST ANNA KINDERKREBSFORSCHUNG

  公开号：WO2020070290A1

  公开（公告）日：2020-04-09

  Disclosed is agroup of chimeric antigen receptors (CARs) consisting of two, three or four CAR molecules, wherein the members of the group of CARs can be different or identical in their amino acid sequences to one another, and wherein each of the CAR molecules of the group comprise at least a transmembrane domain and an ectodomain comprising either an antigen binding moiety or a binding site to which another polypeptide is able to bind, wherein the another polypeptide comprises an antigen binding moiety; wherein each CAR molecule of the group comprises at least one dimerization domain, wherein this dimerization of a pair of dimerization domains is either induced by a regulating molecule and optionally reduced by another regulating molecule, or occurs in the absence of a regulating molecule and is reduced by a regulating molecule, and wherein the ectodomain of each CAR molecule of the group in its prevalent conformation is free of cysteine amino acid moieties which are able to form intermolecular disulphide bonds with other CAR molecules of the group, respectively, and wherein the antigen binding moieties of the CAR molecules of the group and of the other polypeptides being able to bind to the CAR molecules of the group are either specific for one target antigen or for a non-covalent or a covalent complex of different target antigens.